# MediScanAI Phase A.1.3 — Independent Remediation Verification Audit Report

**Auditor Role:** Independent Benchmark Integrity Auditor  
**Audit Target:** Phase A.1.2 Deliverables and Remediated Source Evidence  
**Audit Directory:** `evaluation/benchmark/research_adjudication/phase_a_1_3_audit/`  
**Execution Context:** Conda environment `med-env` (92 unit tests passing)  
**Audit Date:** October 14, 2026  

---

## 1. Executive Summary & Audit Area Verdicts

An independent, read-only verification of the Phase A.1.2 deliverables was conducted against the physical workspace files and live official source endpoints.

| Audit Area | Scope of Audit | Verdict | Summary Finding |
|---|---|:---:|---|
| **Audit 1: Artifact Integrity** | Schema validation, row/case counts, 1-to-1 CSV parity, negative control contract, null review timestamps, gold file size. | **PASS** | 50 canonical cases, 57 candidate judgments, 62 proposed judgments & reviewer rows (0 mismatches), `gold_judgments.jsonl` is 0 bytes. |
| **Audit 2: DailyMed Source Verification** | Official DailyMed REST API & Web resolution, SPL titles, active ingredient matching, monotherapy vs combination verification. | **PASS** | All 14 remediated setIDs return 1 active SPL element via API and resolve to live HTTP 200 pages with exact product matching. |
| **Audit 3: Relevance & Provenance** | Grade stability, rationale traceability, medical claim support, separation of preliminary AI status from gold labels. | **PASS** | Grade distribution is identical to Phase A.1.1 (0 grades altered); every row contains traceable source URL and rationale. |
| **Audit 4: Reproducibility & Git State** | Git status, clean tracked working tree, test suite execution, non-interference verification. | **PASS** | All 92 unit tests pass in 2.77s; clean git state on tracked files; `entity_resolution/` strictly untouched. |

---

## 2. Audit 1: Artifact Integrity & Reconciled Counts

### Exact File-Derived Metric Table
| Metric / Check | Value | Verification Method | Status |
|---|:---:|---|:---:|
| Unique Benchmark Query Cases | **50** | `len(set(q['case_id'] for q in queries))` | **PASS** |
| Canonical Case ID Range | `MED-BENCH-001` to `MED-BENCH-050` | Contiguous sequential ID check | **PASS** |
| Candidate Judgments Count | **57** | Line count `candidate_judgments.jsonl` | **PASS** |
| Proposed Judgments Count | **62** | Line count `proposed_judgments.jsonl` | **PASS** |
| Reviewer Packet CSV Rows | **62** | Data row count `reviewer_packet.csv` | **PASS** |
| Proposed vs Reviewer CSV Parity | **0 mismatches** | Field-by-field check (case, evidence, grade, type, channel) | **PASS** |
| Negative-Control Rows Count | **5** | Filter `evidence_id == 'none'` | **PASS** |
| Official Gold File Size | **0 bytes** | `os.path.getsize('gold_judgments.jsonl')` | **PASS** |
| Preliminary Status Compliance | **62 / 62 (100.0%)** | `judgment_status == 'preliminary_ai_annotated'` | **PASS** |
| Null Review Timestamps | **62 / 62 (100.0%)** | `reviewed_at is None` and `reviewer_id == 'ai_research_assistant'` | **PASS** |

### Case Count vs. Row Count Reconciliation
The benchmark exhibits a structured relationship between unique cases and evaluated rows:
- **Total Unique Cases:** **50** (`MED-BENCH-001` through `MED-BENCH-050`).
- **Total Proposed Rows:** **62** (45 cases have 57 corpus candidate rows; 5 negative control cases have 5 explicit reference rows).
- **Review Requirement Partition:**
  - `review_requirement == "none"`: **29 unique cases**, accounting for **37 candidate rows** (32 corpus candidates + 5 negative controls).
    - Scope: Cases `001–020` (drug lookup/relationship), `036` (metformin candidate), `041–045` (negative controls), `046` (atorvastatin lookup), `048` (cetirizine lookup), and `049` (cinzan adverse reaction).
  - `review_requirement == "qualified_medical_review"`: **21 unique cases**, accounting for **25 candidate rows**.
    - Scope: Cases `021–035` (symptom-disease retrieval, multi-symptom, synonym variants), `037–040` (ambiguous clinical differentials), `047` (amoxicillin query with renal failure candidate), and `050` (tension headache symptoms).
  - **Case Overlap:** **0 cases**. No single case has candidates spanning both non-clinical and clinical review requirements. Therefore, the union of unique cases is $29 + 21 = 50$, and the row sum is $37 + 25 = 62$.

---

## 3. Audit 2: DailyMed Source Verification Findings

Every remediated DailyMed setID was programmatically probed against the live DailyMed REST API (`https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?setid=<setid>`) and web endpoint (`https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=<setid>`):

| Source Key | Product Name / Benchmark Entity | Verified SetID | Official DailyMed SPL Title | Formulation & Active Ingredient Verification | Verdict |
|---|---|---|---|---|:---:|
| `drug_53548` | Lipitor (Atorvastatin Calcium) | `a60cc18b-0631-4cf0-b021-9f52224ece65` | `LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [VIATRIS SPECIALTY LLC]` | Oral film-coated tablet; innovator brand for atorvastatin calcium trihydrate. | **PASS** |
| `NC-043` | Lipitor COVID-19 Negative Control | `a60cc18b-0631-4cf0-b021-9f52224ece65` | `LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [VIATRIS SPECIALTY LLC]` | Package insert confirms zero antiviral indications or efficacy claims for COVID-19. | **PASS** |
| `drug_2765` | Advil (Ibuprofen 200 mg) | `1a665e64-9f30-be37-4a83-38789f1f1e89` | `ADVIL (IBUPROFEN) TABLET, COATED [HALEON US HOLDINGS LLC]` | Coated tablet; active ingredient Ibuprofen 200 mg. | **PASS** |
| `drug_25219` | Zyrtec (Cetirizine HCl 10 mg) | `568960cf-2c8f-f1b0-e063-6294a90aebc7` | `ZYRTEC ALLERGY (CETIRIZINE HYDROCHLORIDE) TABLET, FILM COATED [SELECT CONSUMER GROUP]` | Film-coated tablet; active ingredient Cetirizine HCl 10 mg. | **PASS** |
| `drug_13249` | Amoxil (Amoxicillin oral susp) | `ec7dd735-dc92-3d29-e053-2a95a90af549` | `AMOXIL (AMOXICILLIN ORAL SUSP) POWDER, FOR SUSPENSION [DIRECTRX]` | Powder for oral suspension; active aminopenicillin antibiotic substance. | **PASS** |
| `drug_640` | Atorvastatin Calcium generic | `d9adb9e4-c495-9530-e5e3-7e3b01d53e4c` | `ATORVASTATIN CALCIUM TABLET, FILM COATED [APOTEX CORP.]` | Unbranded oral film-coated tablet; generic atorvastatin calcium trihydrate. | **PASS** |
| `drug_353` | Amoxicillin generic capsule | `61a9829b-4792-4caa-b75a-b84812f28d4a` | `AMOXICILLIN CAPSULE [CHARTWELL GOVERNMENTAL & SPECIALTY RX, LLC]` | Oral capsule; generic amoxicillin trihydrate. | **PASS** |
| `drug_44` | Ibuprofen 200 mg generic | `152b0c90-b0c3-4b1b-9e93-4b4c6b3118bd` | `IBUPROFEN TABLET, FILM COATED [A-S MEDICATION SOLUTIONS]` | Oral film-coated tablet; generic ibuprofen 200 mg. | **PASS** |
| `drug_110` | Cetirizine HCl generic tablet | `d55dfce1-acef-3342-e053-2a95a90a4b83` | `CETIRIZINE HYDROCHLORIDE TABLET, COATED [GRANULES PHARMACEUTICALS INC.]` | Oral coated tablet; generic cetirizine hydrochloride 10 mg. | **PASS** |
| `drug_345` | Metformin HCl extended release | `ef77c7dd-a65f-4adc-a0d9-a93779b459a0` | `METFORMIN HYDROCHLORIDE TABLET, EXTENDED RELEASE [AUROBINDO PHARMA LIMITED]` | Extended-release oral tablet; generic metformin hydrochloride biguanide. | **PASS** |
| `drug_116` | Amazon Basic Care Omeprazole | `10efef7c-bdf4-36cf-e063-6394a90a8c0f` | `AMAZON BASIC CARE OMEPRAZOLE (OMEPRAZOLE) TABLET, DELAYED RELEASE [AMAZON.COM SERVICES LLC]` | Delayed-release oral tablet; 20 mg omeprazole proton pump inhibitor. | **PASS** |
| `drug_923` | Lisinopril generic monotherapy | `34ebeea1-6812-4697-84c4-b2ae4f39e55f` | `LISINOPRIL TABLET [BLUEPOINT LABORATORIES]` | Oral monotherapy tablet; unbranded single-ingredient Lisinopril. | **PASS** |
| `drug_473` | Lisinopril + HCTZ combination | `515f735c-5dba-43d9-8a58-97a319cafd56` | `LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLET [LUPIN PHARMACEUTICALS, INC.]` | Fixed-dose combination tablet; verified both Lisinopril and Hydrochlorothiazide. | **PASS** |
| `drug_5711` | Ciprofloxacin in Dextrose 5% | `cbbbf939-3219-4515-a48e-ca264daa4d07` | `CIPROFLOXACIN IN DEXTROSE (CIPROFLOXACIN) INJECTION, SOLUTION [HOSPIRA, INC.]` | Intravenous injection solution; premix in 5% dextrose vehicle. | **PASS** |

### Special Clinical Verification Checks:
1. **Combination Product Integrity (`drug_473` vs `drug_923`):**
   - The label for `drug_473` (`515f735c-5dba-43d9-8a58-97a319cafd56`) was verified to contain **both** active ingredients (Lisinopril + Hydrochlorothiazide) in a co-formulated tablet.
   - The monotherapy label for `drug_923` (`34ebeea1-6812-4697-84c4-b2ae4f39e55f`) contains exclusively single-ingredient Lisinopril. No cross-contamination between monotherapy and combination labels occurred.
2. **Negative Control Verification (`NC-043`):**
   - The verified Lipitor package insert confirms approved indications for cardiovascular risk reduction and hyperlipidemia, with zero antiviral indications for COVID-19, justifying relevance grade 0 under Rule 4.9.
3. **Unresolved Product/Source Mismatches:**
   - **0 unresolved items.** Logged in `unresolved_findings.jsonl` (empty file).

---

## 4. Audit 3: Relevance and Provenance Stability

- **Relevance Grade Continuity:**
  - Grade 3: **45 rows** (72.6%)
  - Grade 2: **11 rows** (17.7%)
  - Grade 1: **1 row** (1.6%) [`MED-BENCH-038` on `disease_chunk_2501`]
  - Grade 0: **5 rows** (8.1%) [`MED-BENCH-041` to `045`]
  - Net grade changes compared to Phase A.1.1 baseline: **0**.
- **Evidence Traceability:**
  - Every non-trivial factual judgment has a verified, resolvable primary source URL.
  - Rationales explicitly articulate the clinical/informational connection to the user query rather than relying solely on keyword co-occurrence.
- **Separation of Annotation States:**
  - The benchmark maintains a strict separation: AI-generated annotations are labeled `preliminary_ai_annotated`, and no judgment has been promoted to gold ground truth.

---

## 5. Audit 4: Reproducibility, Git State, and Test Suite

### Git Working Tree Audit
- `git status --porcelain` check confirms **zero tracked files modified**:
  ```
  ?? evaluation/
  ?? tests/unit/test_evaluation_benchmark.py
  ?? tests/unit/test_retrieval_evaluation.py
  ```
- No commits, merges, pushes, resets, or dependency installations occurred.
- `evaluation/benchmark/gold_judgments.jsonl` remains untouched at 0 bytes.
- `entity_resolution/` was never accessed or referenced.

### Test Suite Execution
Executed `pytest tests/unit/ -v`:
- **Result:** **92 passed in 2.77s**.
- All benchmark schema tests, retrieval pooling contracts, and negative-control validation tests pass cleanly.

---

## 6. Evaluation Readiness Decision & Recommendations

1. **Human Clinical Review Workflow:**
   - **READY TO BEGIN.** The research packet [reviewer_packet.csv](file:///Users/sj/Documents/mediscanai/evaluation/benchmark/research_adjudication/reviewer_packet.csv) and [proposed_judgments.jsonl](file:///Users/sj/Documents/mediscanai/evaluation/benchmark/research_adjudication/proposed_judgments.jsonl) are fully verified with authentic regulatory URLs and clinical rationales. A licensed physician or clinical pharmacist can safely commence human adjudication.
2. **Official Retrieval Metrics Evaluation:**
   - **STRICTLY BLOCKED.** Official retrieval evaluation requires human-verified gold labels. `gold_judgments.jsonl` must remain empty until the clinical review workflow is completed and signed off.
3. **Ragas Answer-Generation Evaluation:**
   - **STRICTLY BLOCKED.** Ragas evaluation cannot begin until human-verified gold ground truth and answer contexts are established. Phase C remains blocked.

---

## 7. Deliverables Generated in `phase_a_1_3_audit/`

1. [independent_audit_report.md](file:///Users/sj/Documents/mediscanai/evaluation/benchmark/research_adjudication/phase_a_1_3_audit/independent_audit_report.md) — This formal audit report.
2. [dailymed_verification.csv](file:///Users/sj/Documents/mediscanai/evaluation/benchmark/research_adjudication/phase_a_1_3_audit/dailymed_verification.csv) — 14-row audit log verifying every DailyMed SPL API response, title, date, and product match verdict.
3. [artifact_integrity.json](file:///Users/sj/Documents/mediscanai/evaluation/benchmark/research_adjudication/phase_a_1_3_audit/artifact_integrity.json) — Machine-readable integrity record tracking exact row counts, parity results, gold file size, and git state.
4. [unresolved_findings.jsonl](file:///Users/sj/Documents/mediscanai/evaluation/benchmark/research_adjudication/phase_a_1_3_audit/unresolved_findings.jsonl) — Unresolved findings ledger (0 findings; empty file confirming all checks passed).
